The White House on Tuesday announced new steps to expand access to Paxlovid, the Covid-19 antiviral pill. But experts say that efforts to reach at-risk Americans remain complex and inefficient.
By: Noah Weiland | April 26, 2022
Adeolu Odewale, right, the owner of Demmy’s Pharmacy in Greenbelt, Md., had been eager to obtain Paxlovid for his high-risk customers,
but so far, he has dispensed it to just seven people. Credit…Shuran Huang for The New York Times
GREENBELT, Md. — Last month, the owner of a small pharmacy here secured two dozen courses of Pfizer’s new medication for treating Covid-19, eager to quickly provide them to his high-risk customers who test positive for the virus.
More than a month later, the pharmacy, Demmy’s, has dispensed the antiviral pills to just seven people. The remaining stock is sitting in neatly packed rows on its shelves here in the suburbs of Washington, D.C. And the owner, Adeolu Odewale, is scrambling to figure out how to get the medication, Paxlovid, to more people as cases have increased over 80 percent in Maryland in recent days.… read more > “With Supply More Abundant, Pharmacies Struggle to Use Up Covid Pills”